LYSANDO-AG
2.8.2021 08:02:09 CEST | Business Wire | Press release
South Korean KOSDAQ listed AMICOGEN Inc. will become the latest shareholder in Lysando AG. The transaction includes an acquisition of shares, a cash contribution to Lysando and a share package to Lysando into AMICOGEN.
The deal means an 8% participation of AMICOGEN into Lysando and 2.69% in shares for Lysando into AMICOGEN. The transactions were negotiated with a 300 Mio. Euro evaluation of Lysando.
Other shareholders of Lysando continue to be majority owner and Chairman of the Board Markus Graf Matuschka von Greiffenclau, Bangkok based SCG, and Lysando’s employees.
The companies have already a productive partnership in place, based on Lysando´s leading platform Artilysin® . It is a globally patented, sustainable and highly effective technology, fighting resistance of microbes, as an alternative to antibiotics and other antimicrobial treatments.
„I am very happy and proud to welcome AMICOGEN as a new shareholder of Lysando. AMICOGEN being such a strong and successfully operating CDMO, Asian markets, in particular China and South Korea, can now be approached faster and with the highest level of sufficiency. Our microbiome-friendly Artilysin® -platform has incredible potential for the benefit of humanity, pets, farmed animals and the environment which can be implemented even better now“, says Lysando´s chairman Markus Graf Matuschka von Greiffenclau.
„Global spreading resistance and our increasing knowledge about the importance of a balanced microbiome require innovation and a new way of thinking. We had been impressed with the potential of Artilysin® from the very beginning. I am looking very much forward pushing our partnership to the next level, intensifying our company´s interfaces and therefore merge know-how to even further drive the success and growth of the Artilysin® -platform.”, says Yong Chul Shin, CEO of AMICOGEN.
Amicogen Inc.
Amicogen Inc., 092040:KOSDAQ develops, produces and markets specialty enzymes and functional food ingredients. The company offers special biocatalysts, enzyme-based new functional materials, health foods, and consumer products.
Lysando AG
Lysando AG is market-leader for antimicrobial proteins, so-called Artilysin®
s.
Artilysin®
s are a new class of molecules showing a high resistance stability and are microbiome- and environmentally-friendly. Artilysin®
s can be employed in all fields, bacteria present a problem like Medical Devices, Human Pharmaceutics, Animal Health and Consumer Care.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210801005009/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
In Line With the LEAP | 28 Portfolio Rotation Strategy, Bureau Veritas Signs an Agreement to Sell Its Oil & Petrochemicals and Coal Testing and Inspection Business30.6.2026 07:30:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), announces that it has entered exclusive negotiations with Triton Partners regarding the sale of its Oil & Petrochemicals and Coal testing and inspection business. This strategic divestment is in full alignment with the Group’s LEAP | 28 strategy. The proposed transaction would include the Oil & Petrochemicals and Coal testing and inspection activities. In 2025, this business generated approximately EUR 450 million in revenue operating a global network across multiple countries, with a significant footprint of operational sites and employees. This business grew at a lower rate than the Group and is margin dilutive. It is included within Bureau Veritas’ “Optimize value and impact” portfolio and reported under the Agri-Food & Commodities division. The transaction supports the strategic objective to increase exposure to higher growth and margin businesses. A key milestone in LEAP | 28 portfolio rotati
Corient Accelerates European Growth With the Addition of Letus Private Office30.6.2026 07:15:00 CEST | Press release
Leading French multi-family office with approximately US$5 billion in assets is Corient’s fourth European acquisition, growing firm’s global assets to approximately US$523 billion Corient today announced an agreement to acquire Letus Private Office (“Letus”), an independent multi-family office and wealth advisory firm serving entrepreneurs, founders and other ultra-high-net-worth individuals and families across France and Europe. The acquisition, subject to closing, builds on recent transactions that have made Corient the world’s largest multi-family office and non-bank wealth manager focused on ultra-high-net worth and high-net-worth clients. Paris-based Letus was founded in 2016 and is led by Managing Partners Anice Chlagou, Stephen Lasry and Alexandre Tsouli, and Partner Sacha Levy. It manages and administers approximately €4.1 billion (about US$5 billion). Letus serves ultra-high-net worth clients, primarily entrepreneurs and their families, providing comprehensive, bespoke service
“BOCCHI THE ROCK!” SeisyunComplex Premiered on June 20!30.6.2026 07:00:00 CEST | Press release
A New Work for “TOKYO Night & Light” — Surpassing 1.4 Million Total Visitors The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625185578/en/ We are pleased to announce that the first screening of “BOCCHI THE ROCK!” SeisyunComplex, a new projection mapping work inspired by the highly popular anime “BOCCHI THE ROCK!”, was held on Saturday, June 20. Following its premiere, the work will be screened throughout the year as part of the weekday and weekend lineup of “TOKYO Night & Light”. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.4 million. As on
Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease30.6.2026 07:00:00 CEST | Press release
Hengrui Pharma, a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique EyeSol® water-free platform technology, announce today that on June 23, 2026, the China National Medical Products Administration (NMPA) has approved Heng Yi® (0.1% cyclosporine ophthalmic solution) for the treatment of patients with dry eye disease, aiming to increase tear secretion in patients with reduced tear production and improve the sign of the disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629052295/en/ Heng Yi Heng Yi® is the first and only water-free 0.1% cyclosporine ophthalmic solution and the second dry eye disease drug product approved in China based on the EyeSol® platform technology, following the approval of Heng Qin® (perfluorohexyloctane ophthalmic solution) in 202
Nebex Raises $30M Seed Round Led by GV to Build Market Infrastructure for the Global Space Economy29.6.2026 17:38:00 CEST | Press release
The new funding and banking relationship allow Nebex to scale the market and unlock the commercial space economy. Nebex, the market infrastructure platform for the global space economy, announced a $30M seed investment led by GV (Google Ventures), with participation from other top-tier venture funds. The company also announced a banking relationship with J.P. Morgan. The capital raise and new banking relationship will help Nebex scale its platform and connect sovereign space programs with the founders and companies building new technologies to serve the space industry. "We built Nebex because we've seen firsthand that ambitious space founders struggle to deliver complex sovereign programs due to the lack of capital markets infrastructure that supports revenue and cashflow. This is something that exists in nearly every other industry," said Tejpaul Bhatia, CEO of Nebex. "Support from these organizations gives Nebex the additional leverage and financial infrastructure to build the global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom